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Background: Non-alcoholic fatty liver disease (NAFLD) is the most common hepatic disor-
der, which poses a significant health burden in the western countries. As the epidemic of
obesity slides health downward, the incidence of NAFLD is evidently increasing.
Aim: We aimed to ascertain the awareness of NAFLD and its risk factors in the general
population, which may be helpful in designing educational tools to promote prevention,
early detection, and treatment of this disorder.
Methods: A survey of 5000 non-institutionalized residents of Brooklyn, NY, USA was con-
ducted. Sixteen items were included in the survey questionnaire including awareness
of fatty liver, predisposing factors of NAFLD, awareness of cirrhosis, and conditions that
advance to cirrhosis. The questionnaire also addressed awareness of prevention, diagnos-
tic methods and treatment of NAFLD, and education of physicians to their patients about
NAFLD.
Results: Overwhelming majority of the subjects was not aware of NAFLD and stated that
their physicians did not have a discussion about NAFLD.
Conclusion: Non-alcoholic fatty liver disease is a preventable liver disorder with limited
treatment options. Thorough counseling by primary care physicians can be of paramount
importance in preventive strategy for NAFLD. We should target our teenage population in
an era of obesity epidemics of all times.
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INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) consists of a spectrum
of liver pathology ranging from steatosis to steatohepatitis, fibro-
sis, cirrhosis, and ultimately hepatocellular carcinoma. In United
States, chronic liver disease and cirrhosis are the tenth leading
cause of death. Metabolic syndrome with its manifestation as non-
alcoholic fatty degeneration is a silent assassin of many organs
including the liver (1–5). As the epidemic of obesity slides health
downward, the incidence of NAFLD is evidently increasing (1).
Two factors responsible for increased prevalence of this condition
are: increasing obesity and the practice of measuring liver function
tests before starting statin therapy (1). NAFLD is the most com-
mon cause of elevated transaminases and cirrhosis of liver. This
disorder is often only suspected and investigated in those with
abnormal liver function tests. However, a recent study demon-
strated that patients could have histological changes of NAFLD
with or without abnormal liver tests. Interestingly, prevalence of
advanced fibrosis was similar between the groups with and without
abnormal liver tests (2).
Non-alcoholic fatty liver disease affects 10–24% of the gen-
eral population in the world. Reported prevalence increases up to
75% in obese individuals. NAFLD affects 2.6% of children and up
to 50% of obese children (3, 4). A combination of diabetes and
obesity may pose an added risk. Up to 100% of obese diabetics
have at least mild steatosis, 50% have steatohepatitis, and 19%
have cirrhosis (6, 7).
The prevalence of NAFLD in United States was recently esti-
mated using ultrasonographic assessment of hepatic steatosis (8).
This study revealed hepatic steatosis in 21.4% and NAFLD in 19%
of the studied population (8). Obesity affects 22.5% of people
20 years or older (9). Steatosis is found in over two-thirds of the
obese population, regardless of diabetic status. More than 90% of
morbidly obese persons have steatosis. Steatohepatitis affects 3%
of lean population, 19% of obese, and up to 50% of morbidly obese
persons (10). Thus, up to 40 million obese individuals may have
changes consistent with NAFLD. Diabetes mellitus affects 7.8% of
US population over the age of 20 years (11). Up to half of these
individuals have NAFLD (8, 12).
Mild to moderate elevation of serum transaminases is often
the only laboratory abnormality found in NAFLD. When this
condition advances to cirrhosis, other abnormalities, includ-
ing increased alkaline phosphatase and γ-glutamyltransferase,
prolonged prothrombin time, hypoalbuminemia, and hyper-
bilirubinemia may be found. Ultrasonography of the liver may
demonstrate increased echogenicity of liver parenchyma and
cirrhosis.
www.frontiersin.org March 2014 | Volume 1 | Article 4 | 1
Ghevariya et al. Awareness of NAFLD
Non-alcoholic fatty liver disease is increasingly recognized as
a major cause of liver damage (13). Body weight is directly pro-
portional to the likelihood of acquiring NAFLD. With increasing
prevalence of obesity in United States, it is an important pub-
lic health issue. No medications have been proved to directly
reduce or reverse liver damage. Gradual weight loss with appro-
priate glycemic and lipid control is helpful (14). Several studies
demonstrated NAFLD as independent risk factors for systemic
cardiovascular disease. Increased risk of coronary artery disease,
prominently in women is associated with NAFLD (15). A recent
study showed NAFLD in 45–54 years age group is a strong inde-
pendent risk factor for cardiovascular death (16). Another study
demonstrated 13% increase in carotid intima–media thickness and
increased plaque formation in patients with NAFLD (17).
The pathophysiology, diagnosis, and treatment of NAFLD
have been vastly investigated but public awareness of NAFLD
is unknown. The aim of this study is to ascertain awareness of
NAFLD and its risk factors in the general population, which may
be helpful in designing educational tools to promote prevention,
early detection, and treatment of this disorder.
MATERIALS AND METHODS
From March 2008 to July 2008, members of the research study
group conducted a written survey with the residents of Brooklyn,
NY, USA. This cross-sectional survey was conducted in public
places such as shopping centers, deli stores, and coffee shops.
All participants were 18 years or older. To achieve the target of
5000 respondents, 6849 individuals were approached to partic-
ipate in a semi-structured interview followed by answering the
survey questionnaire and 1849 declined to participate. After the
subject agreed to participate and fill out the survey, our surveyor
indicated that fatty liver is fat deposition in the liver and cirrho-
sis is when liver failure begins. After this briefing, the subject was
allowed to complete the questionnaire (Figure 1). The study group
FIGURE 1 | Survey questionnaire. NAFLD, non-alcoholic fatty liver disease.
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of GI faculties, hepatologists, fellows, medical residents, statisti-
cians, and nutritionists developed a comprehensive questionnaire.
The questionnaire was refined after discussion with a focus group.
The average time burden for filling out the questionnaire was
approximately 2 min.
Sixteen items were included in the survey questionnaire: demo-
graphics, level of education, awareness of fatty liver, awareness of
cirrhosis, conditions that can advance to cirrhosis, predisposing
factors of NAFLD. The questionnaire also addressed awareness
of prevention, diagnostic methods and treatment of NAFLD, and
education by physicians to their patients about NAFLD.
MEASUREMENTS
Data collected were entered into Analyse-it v2.05 software
(Analyse-it Software Ltd, Leeds, UK). Data entry errors were
resolved by reference to data collection sheets. Pearson’s chi-square
was conducted using Analyse-it v2.05 to explore statistical signifi-
cance regarding public awareness of fatty liver among different age
groups, gender, or education level.
The institutional review board of The Brooklyn Hospital Cen-
ter, Brooklyn, NY, USA approved the study protocol. Selected
survey responses are shown in Table 1.
RESULTS
Study population comprised of 52% males and 48% females. Forty
percent were 20–40 years old, 33% were 41–60 years old, 15% were
more than 60 years old, and 12% were<20 years of age. Fifty three
percent self-reported as African-American, 33% Caucasians, 10%
Hispanics, and the remaining 4% were Asians and other ethnic
groups.
In fact, 98% of the study population stated that their physi-
cians did not have a discussion regarding NAFLD. Only 20% of
the respondents have heard about cirrhosis of liver. Upon further
questioning, 84% of the subjects stated that they were not aware
of the conditions that can potentially cause NAFLD or cirrhosis of
the liver respectively (Figure 2).
Overwhelming majority (70%) of the study population
believed that NAFLD is hereditary and only 2% the population
recognized NAFLD as a preventable condition. Similarly, 96% of
the subjects were unaware of the reversibility of NAFLD in its early
stage. Only 5% of the subjects thought that NAFLD could occur
in a non-alcoholic individual.
Ninety-three percent of the subjects were not sure how this con-
dition is diagnosed. Ninety-five percent did not feel that fat depo-
sition in the liver could cause serious health problems (Figure 3).
Similarly, 93% did not acknowledge the components of metabolic
syndrome.
SUBGROUP ANALYSIS
There was no statistically significant difference between male
and female regarding awareness of NAFLD. Similarly, both
men and women thought that fatty liver is hereditary. Par-
ticipants with lower education level (up to the high school)
were aware of cirrhosis more than the subjects with advanced
degrees (p< 0.0001) and knew that alcohol drinking could lead to
cirrhosis (p< 0.0001). There was no significant difference between
age groups of <20 years old and more than 20 years old regard-
ing knowledge of cirrhosis (8 vs. 889, p= 0.8625). This finding
Table 1 | Selected survey responses.









Elementary school 2022 41
High school 1790 36
College 869 17
Postgraduate 319 6
Has your doctor ever mentioned fatty liver?
No 4923 98
Yes 77 2
Have you ever heard about cirrhosis?
Yes 989 20
No 4011 80
Which of the following you think can advance to cirrhosis?
Alcohol abuse 309 6
Hepatitis 327 6.5
Fatty liver 126 2.5
Other 3 0.06
Do not know 4235 84.7
Which of these conditions you think can cause fatty liver
Obesity 394 8
Diabetes 242 5
Alcohol abuse 43 0.7
High cholesterol 90 1
Lack of exercise 57 1
Other 21 0.3
Do not know 4153 83
Is fatty liver hereditary?
Yes 3525 70
No 1475 30
Is there a treatment available for fatty liver?
Yes 64 1
No 40 1
Do not know 4896 98
Fatty liver is preventable
True 96 2
False 259 5
Do not know 4645 93
Do you think fatty liver can be reversible in its early stage?
Yes 105 2
No 90 2
Do not know 4805 96
Do you think fat in the liver can cause a serious health problem?
Yes 211 4
No 53 1
Do not know 4736 95
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FIGURE 2 | Awareness of etiologies of NAFLD.
FIGURE 3 | Survey response for (A) fatty liver is preventable. And (B) do you think fat in the liver can cause a serious health problem?
remained true for subgroup analysis of ages <20, 21–40, 41–
60, and above 60 years (20.64% “yes” responses vs. 79.36% “no”
responses, p= 0.012). There is no statistical difference between
responses by males and females regarding their knowledge of cir-
rhosis [502, 10.04% (males) vs. 487, 9.78% (females) for “yes”
response].
Similar percentage of subjects with higher education thought
that alcohol and hepatitis could lead to cirrhosis. Study population
of<20 year of age reported significantly less interaction with their
physicians in discussing about fatty liver (8 vs. 889, p< 0.001).
After excluding “not sure” responses, respondents of <20 years of
age reported sonogram as the method for diagnosing fatty liver at
a greater frequency (p< 0.05).
DISCUSSION
Non-alcoholic fatty liver disease is not a benign disease. Progres-
sive liver biopsies have shown histological progression of steatosis
into fibrosis in 32%, development of cirrhosis in 20%, and liver-
related death in 12% of patients over 10 years (18). Pathologic
effects of this disorder also extend to the cardiovascular system
(15, 16). Conditions such as diabetes mellitus, obesity, dyslipi-
demia, hypertension, and oxidative stress play a critical role in
pathophysiology of this condition. NAFLD, with its potential to
affect younger, non-obese, and non-diabetic individual is a major
public health problem. Widely approached therapy of this disor-
der remains weight loss and appropriate glycemic and lipid control
(19). No treatment has proved to ameliorate or to prevent progres-
sion of NAFLD (20). Higher overall and liver-related mortality is
observed in general US population with NAFLD (18). Recent stud-
ies proposed use of vitamin E and pioglitazone in the treatment of
NAFLD (21). Therefore, preventive measures are the cornerstone
to tackle this soaring public health problem.
This study assessed the knowledge and attitude of the gen-
eral population toward NAFLD and its precipitating factors.
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Overwhelming majority of the participants had little awareness of
NAFLD regardless of their age, gender, or educational status. Vast
majority of them stated that their physicians never mentioned
NAFLD to them but respondents of <20 years of age reported
significant less interaction with their physicians. A recent study
demonstrated insufficient knowledge of primary care physicians
about NAFLD (22). Respondents of all age groups reported obe-
sity as the culprit for NAFLD but they were not aware of the other
risk factors for NAFLD. Different levels of education had differ-
ent opinions about risk factors for cirrhosis. Respondents of lower
education reported that they were aware of cirrhosis and alcohol
could lead to cirrhosis. The majority of respondents reported that
fatty liver was hereditary. This implies the public misperception of
this disease and its importance in implementing tools for public
education.
The limitations of the study include the possibility of sampling
errors. As with most cross-sectional surveys, our study popula-
tion may not be entirely representative of the general population.
Respondents had a chance to choose more than one answers in
some questionnaires in the survey but majority of the participants
chose only one answer.
CONCLUSION
Our study proved the fact that surprisingly higher percentage of
our general population remains unrecognized of this silent but
concerning disease and patient education programs were lack-
ing. We hope that this study will draw attention for the urgent
need for an education campaign among physicians and the general
population.
Awareness of NAFLD must be promoted for prevention, early
detection, and treatment. Thorough counseling by primary care
physicians can be of paramount importance in preventive strategy
for NAFLD. Educational tools including mass media should be
utilized to increase awareness of NAFLD.
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